Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Trastuzumab | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, other |
| Sample | BC tissues, HER2-positive BC cell lines (SKBR3, HCC1954), HER2-negative BC cell line (MDA-MB-231) |
| Expression Pattern | up-regulated |
| Function Description | H19 is a trastuzumab-responsive lncRNA and its expression was upregulated in a trastuzumab-resistant breast cancer cell. Downregulation of H19 restored the sensitivity of trastuzumab-resistant cells to this drug. The expression of H19 significantly correlated with TNM stage. Patients with higher expression of H19 showed an evidently shorter progression-free survival than those with low H19 expression. H19 overexpression was negatively correlated to the trastuzumab-therapy response. |
| Pubmed ID | 31436255 |
| Year | 2019 |
| Title | Correlation Between Long Non-Coding RNAs (lncRNAs) H19 Expression and Trastuzumab Resistance in Breast Cancer |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |